Table 2.
Association between JMJD2A expression and clinicopathological parameters in 155 cases of breast cancer
| |
Total |
JMJD2A |
P
-value |
Correlation coefficient |
|||
|---|---|---|---|---|---|---|---|
| |
|
0 (−) |
1 (+) |
2 (++) |
3 (+++) |
|
|
| n = 11 | n = 56 | n = 53 | n = 35 | ||||
| ERα |
|
|
|
|
|
|
|
| Negative |
52 |
4 |
18 |
17 |
13 |
0.778 |
−0.023 |
| Positive |
103 |
7 |
38 |
36 |
22 |
||
| PR |
|
|
|
|
|
|
|
| Negative |
77 |
7 |
22 |
26 |
22 |
0.147 |
−0.117 |
| Positive |
78 |
4 |
34 |
27 |
13 |
||
| HER2 |
|
|
|
|
|
|
|
| Negative |
7 |
0 |
3 |
2 |
2 |
0.742 |
−0.027 |
| Positive |
148 |
11 |
53 |
51 |
33 |
||
| ARHI |
|
|
|
|
|
|
|
| Negative |
63 |
20 |
12 |
17 |
14 |
0.016* | −0.194 |
| Positive | 92 | 40 | 24 | 21 | 7 | ||
*P <0.05. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; ARHI, Aplasia Ras homolog member I.